Skip to main content
Premium Trial:

Request an Annual Quote

Barry Greene, Robert Saltmarsh, Nick Venuto

Premium
Alnylam Pharmaceuticals has promoted Barry Greene from COO to president and COO, the firm announced last week. He will continue to report to CEO John Maraganore. Prior to Alnylam, Greene was general manager of oncology at Millennium Pharmaceuticals.
 

 
Robert Saltmarsh, vice president and chief financial officer at Nanogen, will retire from his position at the end of February 2008, the firm said last week. Saltmarsh will continue to consult with Nanogen through the end of next year as needed.
 
Nick Venuto, executive director of finance, has been named as Saltmarsh's successor. Venuto has been responsible for financial operations and reporting for the last four years.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.